Skip to main content
. 2018 Jul 31;11:4451–4459. doi: 10.2147/OTT.S167614

Figure 5.

Figure 5

Metformin inhibited CDK1 expression and cell proliferation via promoting miR-378 level in HCC cells.

Notes: HepG2 cells were pretreated with miR-378 inhibitor. After 12 h, cells were then treated with metformin (50 mM) for 24 h. (A) Western blotting assay showed that decreased CDK1 expression caused by metformin treatment was reversed by miR-378 inhibitor in HepG2 cells. Data are expressed as mean ± SD, n=3, *P<0.05. (B) The CCK-8 assay showed that the inhibition of cell proliferation caused by metformin treatment was reversed by miR-378 inhibitor in HepG2 cells. Absorbance at 450 nm was measured. Data are expressed as mean ± SD, n=3, *P<0.05. (C) Cell cycle assay showed that G2/M arrest caused by metformin treatment was reversed by miR-378 inhibitor in HepG2 (19%–10.4%) cells. Data are expressed as mean ± SD, n=3, *P<0.05. (D) Cell apoptosis assay showed that metformin caused cell apoptosis of HepG2 cells could not be inhibited by miR-378 inhibitor. Data are expressed as mean ± SD, n=3, *P<0.05.

Abbreviations: CCK-8, Cell Counting Kit-8; HCC, hepatocellular carcinoma.